Screener
ImmunityBio, Inc. IBRX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Related-party convertible note payable, at fair value (Note 14) | 678,386 | 477,093 |
| Revenue interest liability (Note 13) | 404,299 | 324,615 |
| Operating lease liabilities, less current portion | 20,062 | 19,732 |
| Operating lease liabilities, less current portion – related parties | 13,085 | 13,715 |
| Derivative liabilities (Note 13) | 23,314 | 19,722 |
| Warrant liabilities (Note 16) | 308,193 | 84,417 |
| Other liabilities | 472 | 424 |
| Total liabilities | 1,515,763 | 1,001,472 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total liabilities?
- ImmunityBio, Inc. (IBRX) reported total liabilities of $1.52B in Q1 2026.
- How has ImmunityBio, Inc.'s total liabilities changed year-over-year?
- ImmunityBio, Inc.'s total liabilities increased by 69.5% year-over-year, from $894.24M to $1.52B.
- What is the long-term trend for ImmunityBio, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total liabilities has grown at a 24.1% compound annual growth rate (CAGR), from $339.87M to $1B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about ImmunityBio, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude